サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：キャリアスクリーニングの世界市場：2023-2030年
市場調査レポート
商品コード
1380420

キャリアスクリーニングの世界市場：2023-2030年

Global Carrier Screening Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 165 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
キャリアスクリーニングの世界市場：2023-2030年
出版日: 2023年09月27日
発行: Orion Market Research
ページ情報: 英文 165 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のキャリアスクリーニング市場は、予測期間（2023-2030年）にCAGR 17.1％で成長すると予測されています。市場の成長は、包括的な検査の開発に起因しています。FirstGene 4-in-1出生前スクリーニング検査の利用可能性は、キャリアスクリーニングと出生前ケアを改善するための幅広い取り組みの一環です。妊娠期間を通じて全体的な遺伝的洞察の必要性が高まっていることに対応して、出生前の健康と遺伝学のいくつかの側面をカバーするこの包括的な検査は、世界のキャリアスクリーニング市場を後押ししています。例えば、2023年1月にはHighlights 2023 Product Launched for Women's Health, Oncology Businessesが発表されました。ソルトレイクシティに本社を置く同社は、非侵襲的出生前スクリーニング、キャリアスクリーニング、胎児と母体の血液適合性をカバーするFirstGene 4-in-1出生前スクリーニング検査を第3四半期に導入する準備を進めています。

セグメント別の展望

血液学的サブセグメントが世界のキャリアスクリーニング市場でかなりのシェアを占めると予想される

医学的条件のうち、血液学的サブセグメントは世界のキャリアスクリーニング市場でかなりのシェアを占めると予想されます。このセグメントの成長は、高度な診断ツールに対する需要の高まりに起因しています。Yumizen H500およびH550分析装置は、ヘルスケア分野におけるより高度で効果的な診断ツールへの需要の高まりを反映した、継続的に進化する診断技術の証です。血液学的検査プロセスは、血液分析装置によってより迅速かつ正確になり、患者ケアを向上させることができます。例えば、2022年7月、堀場メディカルは、改良された機能、新機能、さらなる利点を備えたポータブル卓上血液分析装置であるYumizen H500およびH550血液学製品ファミリーの新製品を発売しました。1時間当たり60件の検査、連続ローディングによる40本のオートノミーチューブ、緊急マニュアルモード、複数の分析モデルおよびサンプリングによるサンプルの実行など、新しいYumizen H500およびH550は、即座に詳細な血液学的レポートを提供することを目的としています。

地域別展望

世界のキャリアスクリーニング市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されます。このうち北米は、嚢胞性線維症などの遺伝性疾患の有病率が高いこと、市場参入企業が増加していること、同地域で提供される検査数が大幅に増加していることから、全世界の市場で突出したシェアを占めると予想されます。

アジア太平洋地域は世界のキャリアスクリーニング市場において著しいCAGRで成長する見込み

すべての地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予想されています。同地域の成長は、遺伝子検査に対する需要の増加と、同地域全体における一般市民の意識の高まりに起因しています。キャリアスクリーニング法の利用可能性と遺伝性疾患に対する一般市民の意識の高まりが、遺伝子検査サービス、特にキャリアスクリーニングに対する需要を高めています。2022年11月のBMC Medical Geneticsによると、先天性欠損症は出生時から存在する異常であり、重大な死亡率、生産性の低下、生活の質の低下を引き起こす可能性があります。新興諸国では、予防接種、下痢や呼吸器感染症の抑制、ヘルスケアの改善など、感染症や栄養学的原因の減少により、胎児死亡率、新生児死亡率、乳児死亡率、小児死亡率に占める先天異常の割合が増加しています。欧米では、早期死亡の29.8％、慢性疾患の29.2％を先天性異常が占めています。インドでは、2010～2013年のサンプル登録システム調査で、先天性奇形と遺伝的障害が、小児死亡率、乳児死亡率、新生児死亡率にそれぞれ4.4％、4.6％、4.0％寄与していると報告されています。遺伝的障害を含む先天性奇形は、社会的汚名を着せ、経済的負担をもたらし、特に資源の乏しい国では生活の質を低下させるため、その予防はすべての国において優先事項です。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • DiaSorin S.p.A.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Eurofins Scientific
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Fulgent Genetics, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • キャリアスクリーニングの世界市場：タイプ別
    • 拡大キャリアスクリーニング
    • ターゲット疾患キャリアスクリーニング
  • キャリアスクリーニングの世界市場：病状別
    • 血液疾患
    • 肺疾患
    • 神経疾患
    • その他（家族性地中海熱（FMF）、脆弱X症候群）
  • キャリアスクリーニングの世界市場：タイプ別
    • DNAシーケンス
    • ポリメラーゼ連鎖反応（PCR）
    • マイクロアレイ
    • その他（次世代シーケンシング（NGS）、スクリーニング条件、消費者直接検査）
  • キャリアスクリーニングの世界市場：エンドユーザー別
    • 病院および診療所
    • リファレンスラボ
    • 政府および公衆衛生プログラム
    • その他（製薬会社およびバイオタイプ企業）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Ambry Genetics Corp.
  • Cepheid
  • Congenica Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Invitae Corp.
  • Laboratory Corporation of America（Labcorp）
  • MedGenome Inc
  • Myriad Genetics, Inc.
  • Natera Inc.
  • PerkinElmer AES
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific
図表

LIST OF TABLES

  • 1. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CARRIER SCREENING FOR OTHER MEDICAL CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION (PCR) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CARRIER SCREENING MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CARRIER SCREENING MARKET SHARE BY MEDICAL CONDITION, 2022 VS 2030 (%)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CARRIER SCREENING MARKET FOR OTHER APPLICATIONS SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CARRIER SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CARRIER SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 20. US CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027829

Title: Global Carrier Screening Market Size, Share & Trends Analysis Report by Type (Expanded Carrier Screening, and Targeted Disease Carrier Screening), by Medical Condition (Hematological, Pulmonary, Neurological, and Others), by Technology (DNA Sequencing, Polymerase Chain Reaction (PCR), Microarrays, and Others), and by End User (Hospitals and Clinics, Reference Laboratories, Government and Public Health Programs, and Others)Forecast Period (2023-2030).

The global carrier screening market is anticipated to grow at a CAGR of 17.1% during the Forecast Period (2023-2030). The market's growth is attributed to development of comprehensive testing. The availability of the FirstGene 4-in-1 prenatal screening test is part of a wider effort to improve carrier screening and prenatal care. In response to the rising need for holistic genetic insights throughout pregnancy, this comprehensive test, that covers several aspects of prenatal health and genetics, is helping to boost the global carrier screening market. For instance, in January 2023, Highlights 2023 Product Launched for Women's Health, Oncology Businesses. The Salt Lake City-based company continues to grow prepared to introduce its FirstGene 4-in-1 prenatal screening test, that covers noninvasive prenatal screening, carrier screening, fetal recessive status, and feto-maternal blood compatibility, in Q3.

Segmental Outlook

The global carrier screening market is segmented on the type, medical condition, technology, and end-user. Based on the type, the market is sub-segmented into expanded, and targeted disease. Based on the medical condition, the market is sub-segmented into hematological, pulmonary, neurological, and others. Based on the technology, the market is sub-segmented into DNA sequencing, polymerase chain reaction (PCR), microarrays, and others. Further, on the basis of end-user, the market is sub-segmented into hospitals and clinics, reference laboratories, government and public health programs, and others. The DNA sequencing subcategory is expected to capture a significant portion of the market share within the technology segment. This is attributed to the increase in humanity's vulnerability to genetic disorders. The market is also anticipated to rise as a result of increased uses for the technology in addition to increased knowledge of genetic testing instead of any ethical problems.

The Hematological Sub-Segment is Anticipated to Hold a Considerable Share of the Global Carrier Screening Market

Among the medical condition, the hematological sub-segment is expected to hold a considerable share of the global carrier screening market. The segmental growth is attributed to the growing demand for advanced diagnostic tools. The Yumizen H500 & H550 analyzers are proof of the continuously evolving diagnostic technology that reflects the growing demand for more sophisticated and effective diagnostic tools in the healthcare sector. The hematological testing process should become faster and more accurate owing to blood analyzers, that can enhance patient care. For instance, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the portable benchtop hematology analyzers with improved functionality, new capabilities, and additional advantages. With a throughput of 60 tests per hour, 40 tubes of autonomy with continuous loading, urgent manual mode, and running samples through several analytical models and sampling, the new Yumizen H500 & H550 have been intended to offer an immediate and thorough hematological report.

Regional Outlook

The global carrier screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to a high prevalence of genetic disorders such as cystic fibrosis, a rise in market participants, and a significant rise in the number of tests offered in the region.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Carrier Screening Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for genetic testing and public awareness across the region. The availability of carrier screening methods and growing public awareness of genetic diseases have raised demand for genetic testing services, especially carrier screening. According to the BMC Medical Genetics, in November 2022, birth defects are abnormalities that are present from birth and can cause significant mortality, reduced productivity, and diminished quality of life. In developing countries, they have contributed to an increasing proportion of fetal, neonatal, infant and childhood mortality owing to a decline in infectious and nutritional causes such as immunizations, control of diarrheal and respiratory infections, and improved healthcare. In the West, birth defects account for 29.8% of early mortality and 29.2% of chronic problems. In India, the Sample Registration System Survey during 2010-2013 reported that congenital malformations and genetic disorders contributed 4.4, 4.6 and 4.0% to childhood mortality, infant mortality and neonatal mortality, respectively. The prevention of birth defects, including genetic disorders, is a priority in all countries, as they cause social stigmatization, economic burden, and diminish quality of life, especially in resource-poor countries.

Market Players Outlook

The major companies serving the global carrier screening market include: Congenica Ltd, Illumina, Inc., Invitae Corp., Myriad Genetics, Inc., Natera Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Congenica, launched a newly developed, industry-first offering at Arab Health 2022 that combines the digital genetic profiles of both potential parents for thorough carrier screening to support family planning decisions.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global carrier screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. DiaSorin S.p.A.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Eurofins Scientific
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Fulgent Genetics, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Carrier Screening Market by Type
    • 4.1.1. Expanded Carrier Screening
    • 4.1.2. Targeted Disease Carrier Screening
  • 4.2. Global Carrier Screening Market by Medical Condition
    • 4.2.1. Hematological Conditions
    • 4.2.2. Pulmonary Conditions
    • 4.2.3. Neurological Conditions
    • 4.2.4. Others (Familial Mediterranean Fever (FMF), and Fragile X Syndrome)
  • 4.3. Global Carrier Screening Market by Type
    • 4.3.1. DNA Sequencing
    • 4.3.2. Polymerase Chain Reaction (PCR)
    • 4.3.3. Microarrays
    • 4.3.4. Others (Next-Generation Sequencing (NGS), Screened Conditions, and Direct-to-Consumer Testing)
  • 4.4. Global Carrier Screening Market by End-User
    • 4.4.1. Hospitals and clinics
    • 4.4.2. Reference Laboratories
    • 4.4.3. Government and Public Health Programs
    • 4.4.4. Others (Pharmaceutical and Biotype Companies)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Ambry Genetics Corp.
  • 6.2. Cepheid
  • 6.3. Congenica Ltd.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. Illumina, Inc.
  • 6.6. Invitae Corp.
  • 6.7. Laboratory Corporation of America (Labcorp)
  • 6.8. MedGenome Inc
  • 6.9. Myriad Genetics, Inc.
  • 6.10. Natera Inc.
  • 6.11. PerkinElmer AES
  • 6.12. Quest Diagnostics Inc.
  • 6.13. Thermo Fisher Scientific